Avidity Partners Management’s Ascendis Pharma A/S ASND Stock Holding History

Avidity Partners Management’s Portfolio ASND Stock Details ASND Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-14,500	Closed	-$2.88M	–	44
2025 Q3	$2.88M	Buy	+14,500	New	+$2.7M	0.66%	33
2025 Q1	–	Sell	-62,000	Closed	-$8.54M	–	70
2024 Q4	$8.54M	Sell	62,000 -57,000	-48%	-$7.49M	0.84%	43
2024 Q3	$17.8M	Buy	+119,000	New	+$16.1M	0.91%	44
2020 Q3	–	Sell	-118,900	Closed	-$17.6M	–	70
2020 Q2	$17.6M	Buy	118,900 +58,900	+98%	+$8.09M	1.13%	36
2020 Q1	$6.76M	Buy	60,000 +17,900	+43%	+$2.33M	0.93%	40
2019 Q4	$5.86M	Buy	+42,100	New	+$4.68M	3.69%	10

Other funds holding ASND

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

Westfield Capital Management Boston, Massachusetts $30.6B AUM 61.81% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return

Artisan Partners Milwaukee, Wisconsin $63.1B AUM 35.51% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

Massachusetts Financial Services Boston, Massachusetts $315B AUM 27.84% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Avidity Partners Management's ASND Position: Q4 2025 in Review

Avidity Partners Management sold out of Ascendis Pharma A/S (ASND) in Q4 2025, closing a stake of 14,500 shares — an estimated $2.88M sold.

Avidity Partners Management first reported a position in ASND in Q4 2019 and held it in 6 quarters. The position peaked at $17.8M in Q3 2024. 302 funds tracked by Wall St. Rank hold ASND as of Q4 2025.

Avidity Partners Management reported no remaining Ascendis Pharma A/S position as of Q4 2025 after selling out during the quarter.
Avidity Partners Management sold 14,500 Ascendis Pharma A/S shares in Q4 2025, an estimated $2.88M.
Avidity Partners Management first reported a position in Ascendis Pharma A/S in Q4 2019 and held it in 6 quarters.
Avidity Partners Management's Ascendis Pharma A/S position peaked at $17.8M in Q3 2024.
302 funds tracked by Wall St. Rank held Ascendis Pharma A/S as of Q4 2025.

Based on Avidity Partners Management's 13F filing for Q4 2025, filed 13 Feb 2026.